Inventor · disambiguated record
Mark E. Salvati
Also filed as: SALVATI MARK · SALVATI MARK E
34 granted patents·13 pending applications·554 citations·filing 1999–2022
97Inventor score
Files withBRISTOL MYERS SQUIBB CO30SALVATI MARK E4AMERICAN CYANAMID CO2AMGEN INC2JANSSEN PHARMACEUTICA NV2
Top patents by PatentIndex Score
47 records- 0198US6288082B1Substituted 3-cyanoquinolinesAMERICAN CYANAMID CO·Filed 1999·Granted Sep 11, 2001·190 cites·15 claims
- 0296US6670386B2Bicyclic modulators of androgen receptor functionBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 30, 2003·55 cites·11 claims
- 0395US6960474B2Method for the treatment of a condition remediable by administration of a selective androgen receptor modulatorBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 1, 2005·82 cites·8 claims
- 0490US7141578B2Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Nov 28, 2006·17 cites·14 claims
- 0590US7001911B2Fused cyclic modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 21, 2006·31 cites·21 claims
- 0687US7790770B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 7, 2010·10 cites·25 claims
- 0787US6992102B2Bicyclic modulators of androgen receptor functionBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jan 31, 2006·16 cites·3 claims
- 0887US6900208B2Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disordersBRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 31, 2005·26 cites·10 claims
- 0985US6953679B2Method for the preparation of fused heterocyclic succinimide compounds and analogs thereofBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Oct 11, 2005·21 cites·4 claims
- 1084US7888376B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 15, 2011·8 cites·17 claims
- 1183US7030112B2Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disordersBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Apr 18, 2006·21 cites·2 claims
- 1282US7517904B2Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Apr 14, 2009·1 cites·3 claims
- 1381US7655688B2Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Feb 2, 2010·5 cites·8 claims
- 1480US6022307ASubstituted dibenzothiophenes having antiangiogenic activityAMERICAN CYANAMID CO·Filed 1999·Granted Feb 8, 2000·30 cites·173 claims
- 1578US7776859B2Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor functionBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Aug 17, 2010·2 cites·17 claims
- 1678US7550458B2Tricycloundecane compounds useful as modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jun 23, 2009·2 cites·11 claims
- 1778US7432267B2Fused cyclic modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Oct 7, 2008·2 cites·14 claims
- 1877US7087636B2Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Aug 8, 2006·9 cites·25 claims
- 1977US6795776B1Crystallographic structure of the androgen receptor ligand binding domainBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 21, 2004·12 cites·3 claims
- 2076US6414156B2Process for preparing azacycloalkanoylaminothiazolesBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Jul 2, 2002·6 cites·34 claims
- 2174US7655689B2Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 2, 2010·1 cites·13 claims
- 2271US8304403B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2010·Granted Nov 6, 2012·2 cites·17 claims
- 2370US6639074B2Process for preparing azacycloalkanoylaminothiazolesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Oct 28, 2003·3 cites·7 claims
- 2468US2008214643A1Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 2564US7470797B2Fused heterocyclic imido and amido compoundsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Dec 30, 2008·1 cites·11 claims
- 2663US6482842B23-aminopyrazole inhibitors of cyclin dependent kinasesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 19, 2002·1 cites·30 claims
- 2758US2025074943A1Dll3 binding peptides and uses thereofAMGEN INC·Filed 2022·Application pending·0 cites
- 2858US2023398147A1Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancerAMGEN INC·Filed 2021·Application pending·0 cites
- 2956US7342034B2Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Mar 11, 2008·0 cites·8 claims
- 3054US8404896B2N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseasesSALVATI MARK E·Filed 2007·Granted Mar 26, 2013·0 cites·2 claims
- 3154US7291637B2Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Nov 6, 2007·0 cites·6 claims
- 3253US6897321B2Process for preparing azacycloalkanoylaminothiazoles (LD 137e)BRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 24, 2005·0 cites·4 claims
- 3351US8642576B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2012·Granted Feb 4, 2014·0 cites·14 claims
- 3451US7225083B2Crystallographic structure of the androgen receptor ligand binding domainBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 29, 2007·0 cites·8 claims
- 3551US2004077605A1Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionFiled 2002·Application pending·0 cites
- 3650US9102599B2N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseasesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Aug 11, 2015·0 cites·2 claims
- 3749US6610724B23-Aminopyrazole inhibitors of cyclin dependent kinasesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Aug 26, 2003·0 cites·25 claims
- 3849US2005159420A1Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disordersFiled 2005·Application pending·0 cites
- 3948US2019270826A1Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 4048US2005256048A1Selective androgen receptor modulators and methods for their identification, design and useSALVATI MARK E·Filed 2005·Application pending·0 cites
- 4147US7468439B2Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Dec 23, 2008·0 cites·12 claims
- 4246US2005124625A1Piperazine derivatives and their use as modulators of nuclear hormone receptor functionFiled 2004·Application pending·0 cites
- 4346US2002058290A1Cell lines and cell-based assays for identification of androgen receptor modulatorsFiled 2001·Application pending·0 cites
- 4446US2004087548A1Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionFiled 2002·Application pending·0 cites
- 4541US2017121420A1Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Application pending·0 cites
- 4640US2003114420A1Fused cyclic modulators of nuclear hormone receptor functionFiled 2001·Application pending·0 cites
- 4738US2004176324A1Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark E. Salvati files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →